Julian Symons
Hoofd Techniek/Wetenschap/O&O bij ALIGOS THERAPEUTICS, INC.
Vermogen: 322 344 $ op 30-04-2024
Actieve functies van Julian Symons
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2018 | - |
Loopbaan van Julian Symons
Eerdere bekende functies van Julian Symons
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-01-2013 | 01-04-2018 |
Opleiding van Julian Symons
| University of Central Lancashire | Undergraduate Degree |
| York University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Verenigd Koninkrijk | 2 |
| Canada | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Julian Symons
- Ervaring